HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 2 July 2012

Horizon scanning

There’s a lot of it about!  The UK’s NIHR Horizon Scanning Centre is worth a visit and provides a monthly newsletter.  In the June edition they report on their latest briefings; VBLOC® vagal blocking therapy for obesity,  HPV OncoTect® E6 E7 mRNA Assay to guide colposcopy referral in cervical cancer screening and Secukinumab for plaque psoriasis.  They also list the most downloaded briefings of the spring, which are; GSK2118436 (dabrafenib) for malignant melanoma: advanced and/or metastatic (stage III or IV)- BRAF V600E mutation - first line, Strontium ranelate (Protelos) for osteoarthritis, Caris Target Now molecular profiling service for solid malignant tumours, Chronic Heart Failure Review,  VERV Patient Managed Transdermal Neuromodulation System for overactive bladder syndrome, Xpert MTB/RIF® test for tuberculosis, DELFIA® Xpress PlGF kit antenatal screening test to predict risk of pre-eclampsia, Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes, Fampridine-PR for multiple sclerosis- impaired mobility - first line and Dabigatran (Pradaxa) for atrial fibrillation - stroke prevention.

Euroscan also has its own newsletter and also highlights the latest reports it has acquired from elsewhere.  These are Technologies for the inactivation/reduction of pathogens in blood products, Peptide receptor radionuclide therapy using somatostatin analogues to treat neuroendocrine tumours, Xgeva - Denosumab and Obinutuzumab with chlorambucil for chronic lymphocytic leukaemia– first line, Genesis™ implantable pulse generator for chronic migraine, Vinflunine (Javlor) with capecitabine for advanced breast cancer, Fostamatinib for rheumatoid arthritis – second line, Racecadotril (Hidrasec) for acute diarrhoea and Ciclosporin A (Cyclokat) for keratoconjunctivitis sicca.

And there is the AHRQ!  They produce Status Update Reports, which are revised every two months, provide a listing and brief description of topics identified through the scanning process and being tracked.  The are currently tracking 930 interventions. They also produce Potential High Impact Reports presenting information on the interventions which are expected to have the highest impact based on feedback on Topic Profiles from a variety of stakeholders. The Potential High Impact reports are revised and updated every six months.